Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
GMABGenmabCatalyst overview
Research summary
This catalyst tracks a Phase 3 update for Epkinly/Epcoritamab (GEN3013) (CD3-CD20 Bispecific) + lenalidomide in Relapsed Or Refractory Diffuse Large B-Cell Lymphoma. The expected timing is based on the latest available company guidance and may change.
EPCORE DLBCL-4 trial. 01/16/26:- Data from Ph3 EPCORE DLBCL-4 fixed-duration epcoritamab plus lenalidomide versus chemoimmunotherapy anticipated in 2026. 02/17/26:- PR No update. 07/23/26:- Phase 3 EPCORE DLBCL-4 topline results were recently disclosed; no new timing provided.
Verification
Confirm timing and program details against the company announcement or filing.